Sort
261,768 grants matching “gene therapy”
Primary Immune Deficiency Treatment Consortium
$1,543,394Jennifer Maxwell Puck · University Of California, San Francisco · U54 · FY2017 · AI
Pathophysiologic and Therapeutic Mechanisms in Aspirin Exacerbated Respiratory Disease
$1,543,357Joshua A Boyce · Brigham And Women'S Hospital · U19 · FY2019 · AI
Pathophysiologic and Therapeutic Mechanisms in Aspirin Exacerbated Respiratory Disease
$1,543,357Joshua A Boyce · Brigham And Women'S Hospital · U19 · FY2020 · AI
Pathophysiologic and Therapeutic Mechanisms in Aspirin Exacerbated Respiratory Disease
$1,543,357Joshua A Boyce · Brigham And Women'S Hospital · U19 · FY2016 · AI
Genetic Metabolic Myopathies--phosphofructokinase/acid Maltase Deficiency
$1,543,256Paul H. Plotz · Arthritis, Musculoskeletal, Skin Dis · Z01 · FY2007 · AR
Gene therapy of cancer
$1,543,070Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Adoptive Cell Transfer Immunotherapy of Cancer
$1,543,070Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Mechanical determinants of organ-selective metastatic colonization, dormancy and outgrowth
$1,542,971Roger D. Kamm · Massachusetts Institute Of Technology · U54 · FY2021 · CA
Center for Research Translation of Systemic Exon-skipping in Muscular Dystrophy
$1,542,768Eric P Hoffman · Children'S Research Institute · P50 · FY2014 · AR
Gene and Pharmacological Therapies for Cystic Fibrosis
$1,542,765William B. Guggino · Johns Hopkins University · P01 · FY2007 · HL
Molecular Basis For The Morphogenesis Of The Inner Ear
$1,542,536Doris Wu · National Institute On Deafness And Other Communication Disorders · ZIA · FY2015 · DC
Defining RAS isoform- and mutation-specific roles in oncogenesis
$1,542,424Channing J Der · Univ Of North Carolina Chapel Hill · P01 · FY2017 · CA
UNIV OF TX SOUTHWESTERN COMPREHENSIVE MED SICKLE CELL CT
$1,542,378University Of Texas Sw Med Ctr/Dallas · U54 · FY2004 · HL
Transcriptional and Epigenetic Signatures of Human Brain Development and Autism
$1,542,279Nenad Sestan · Yale University · U01 · FY2014 · MH
Formulation of Rational Therapy of Nephrolithiasis
$1,542,038Orson W Moe · Ut Southwestern Medical Center · P01 · FY2008 · DK
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
$1,542,032Michael A Pulsipher · Children'S Hospital Of Los Angeles · U01 · FY2019 · AI
Gene expression and regulation in endocrine cancers
$1,541,934Electron Kebebew · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
NIAMS: CORT
$1,541,891Robert A Lafyatis · Boston University Medical Campus · P50 · FY2013 · AR
Immunological Strategies to Modulate SIV Rebound Following ART Interruption
$1,541,832Michael R Betts · University Of Pennsylvania · P01 · FY2019 · AI
Discovery of Novel Proteomic Targets for Treatment of Alzheimer's Disease
$1,541,709Allan I Levey · Emory University · U01 · FY2016 · AG
Joint Pain on a Chip: Mechanistic Analysis Therapeutic Targets and an Empirical Strategy for Personalized Pain Management
$1,541,708Michael S Gold · University Of Pittsburgh At Pittsburgh · UG3 · FY2019 · TR
Pediatric Oncology Branch Behavioral Science Core
$1,541,507John Glod · Division Of Basic Sciences - Nci · ZID · FY2025 · CA
Formulation of Rational Therapy of Nephrolithiasis
$1,541,487Orson W Moe · Ut Southwestern Medical Center · P01 · FY2006 · DK
Novel Therapeutics for FSHD
$1,541,442Charles P Emerson · Univ Of Massachusetts Med Sch Worcester · P50 · FY2020 · HD
Novel Therapeutics for FSHD
$1,541,442Charles P Emerson · Univ Of Massachusetts Med Sch Worcester · P50 · FY2022 · HD